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Bone microenvironmentA major cause of morbidity in patients with multiple myeloma is the development and progression of bone dis-
ease. Myeloma bone disease is characterized by rampant osteolysis in the presence of absent or diminished bone
formation. Heparanase, an enzyme that acts both at the cell-surface and within the extracellular matrix to de-
grade polymeric heparan sulfate chains, is upregulated in a variety of human cancers including multiple myelo-
ma. We and others have shown that heparanase enhances osteoclastogenesis and bone loss. However, increased
osteolysis is only one element of the spectrum of myeloma bone disease. In the present study, we hypothesized
that heparanase would also affect mesenchymal cells in the bone microenvironment and investigated the effect
of heparanase on the differentiation of osteoblast/stromal lineage cells. Using a combination of molecular, bio-
chemical, cellular and in vivo approaches, we demonstrated that heparanase signiﬁcantly inhibited osteoblast
differentiation and mineralization, and reduced bone formation in vivo. In addition, heparanase shifts the differ-
entiation potential of osteoblast progenitors from osteoblastogenesis to adipogenesis. Mechanistically, this shift
in cell fate is due, at least in part, to heparanase-enhanced production and secretion of theWnt signaling pathway
inhibitor DKK1by both osteoblast progenitors andmyeloma cells. Collectively, these data provide important new
insights into the role of heparanase in all aspects of myeloma bone disease and strongly support the use of
heparanase inhibitors in the treatment of multiple myeloma.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Multiple myeloma (MM) is a hematologic malignancy characterized
by the development of progressive and destructive osteolytic bone dis-
ease that is associated with diminished numbers of marrow stromal
cells and osteoblasts [17,27]. Despite recent advances in treatment
strategiesmyeloma remains largely incurable,with renal failure and im-
munosuppression as well as bone destruction as the major causes of
morbidity [11,14,27]. Numerous studies have shown that the rampant
osteolysis in myeloma results from the uncoupling of osteoclastic
bone resorption and osteoblastic bone formation [14,17,27]. However,
the molecular mechanisms regulating these events are not fully
understood.gy, University of Alabama at
gham, AL 35294, USA. Fax: +1
c. Open access under CC BY license.Heparanase is an enzyme that cleaves the heparan sulfate chains of
proteoglycans into shorter chain length oligosaccharides [2,32] and
is upregulated in a variety of human tumors, including myeloma
[5,9,10,15,19,21,29]. We have demonstrated that increased levels of
heparanase dramatically enhancemyeloma tumor growth, angiogenesis,
and the spontaneousmetastasis of tumor cells to bone [18,26,33,35]. Re-
cently, we reported that the expression of heparanase by myeloma cells
markedly increased local and systemic osteolysis [36].
However, whether heparanase also contributes to the decreased os-
teoblast compartment common in myeloma bone disease remains un-
known. In the present study, we determined the mechanism(s) by
which heparanase modiﬁes the development and/or activity of mesen-
chymal lineage cells that differentiate into osteoblasts and adipocytes in
the bone marrow microenvironment.
Methods
Cells and reagents
The CAG myeloma cell line was established at the University of
Arkansas for Medical Sciences (Little Rock, AR) as described previously
11J. Ruan et al. / Bone 57 (2013) 10–17[3]. CAG cells have a low level of endogenous heparanase expression
and were previously transfected with empty vector (HPSE-low) or
with vector containing the cDNA for the active form of human
heparanase (HPSE-high) [16,25,33,35]. The murine C3H10T1/2 and
ST2 pre-osteoblast cell lines were obtained from ATCC (Manassas, VA)
and cultured as described below.
Recombinant human heparanase (rHPSE) and heparanase antibodies
were kindly provided by Dr. Israel Vlodavsky (Technion, Haifa, Israel).
Dickkopf1 (DKK1) inhibitor was purchased from Millipore (Billerica,
MA); active and total β-catenin antibodies were purchased from Cell
Signaling (Danvers, MA); human osteocalcin and mouse peroxisome
proliferator-activated receptor gamma (PPARγ) antibodies were
obtained from Abcam (Cambridge, MA); and mouse Runt-related tran-
scription factor 2 (Runx2) antibody was purchased from MBL (Woods
Hole, MA). Human and mouse DKK1 ELISA kits were obtained from
R&D Systems (Minneapolis, MN). ALP and Oil Red O staining kits and
β-actin antibody were purchased from Sigma (St. Louis, MO); and the
Von Kossa staining kit was from Polysciences (Warrington, PA).
Animals
All animals were used in this study according to the NIH Guide for the
Care and Use of Laboratory Animals andwere approved under local insti-
tutional guidelines for the humaneuse of animals in research. SCID (CB.17
scid/scid) and C57BL/6 mice were purchased from Harlan Laboratories,Fig. 1.Heparanase suppresses bone formation in animal model of multiple myeloma. Human fe
left] or HPSE-high [bottom-left]myeloma cells) and contralateral bone (uninjected)were harve
osteoblasts (arrows). A-top: Primary and contralateral bones harvested from themice bearing H
contralateral bones harvested frommice bearing HPSE-high tumors. Originalmagniﬁcation, ×4
tralateral bones of the mice bearing HPSE-low or HPSE-high tumors (Mean ± SEM per mm ofInc. (Indianapolis, IN) and housed in individual cages (5 per cage) in
temperature (22 °C) and humidity (50%) controlled rooms having a
12 h light/12 h dark cycle with food and water ad libitum. All animal ex-
periments were performed under a UAB IACUC approved protocol.
SCID-hu model, myeloma bone marrow specimens and
immunohistochemistry
The SCID-hu is a well described animal model in which human fetal
long bones (Advanced Bioscience Resources, Inc., Alameda, CA) are im-
planted subcutaneously on each side of the dorsum of SCID mice
[33,34,37]. 105 CAG HPSE-low or HPSE-high cells were injected directly
into the cut endof one humanbone graft (primary bone) in eachmouse,
whereas the contralaterally implanted human bones were not injected
with tumor cells (7mice in each group). Eight weeks after the injection
of tumor cells, themicewere euthanized. Tumor-injected human bones
and non-injected contralateral human boneswere collected andﬁxed in
10% neutral-buffered formalin and embedded in parafﬁn as described
[36]. The parafﬁn-embedded bone sections were then stained with
human osteocalcin antibody according to the manufacturer's recom-
mendations and the numbers of osteocalcin positive osteoblasts on
the surface of trabecular bones were counted [25,33].
Twenty eight parafﬁn-embedded bone marrow core biopsy speci-
mens of myeloma patients, obtained from the Department of Pathology
at UAB, were stained for both heparanase and osteocalcin. Thetal boneswere implanted into SCIDmice. (A) Primary bone (injectedwith HPSE-low [top-
sted and stained for human osteocalcin. The brown-colored cells along the bone surface are
PSE-low tumors. Many osteoblasts are visible on the bone surface. A-bottom: Primary and
00. (B) The number of osteoblasts on bone surfacewasmeasured in both primary and con-
bone surface; n = 7). Signiﬁcance is indicated for each comparison in each panel.
12 J. Ruan et al. / Bone 57 (2013) 10–17experimental procedures and protocols were approved by the UAB Insti-
tutional ReviewBoard. Scoring for staining densitieswas determined in a
blinded fashion by two different readers as described previously [18,36].
Preparation of conditioned medium (CM) of HPSE-low and HPSE-high cells
HPSE-low and HPSE-high CAG myeloma cells were seeded at a con-
centration of 5 × 105 cells/ml in RPMI 1640 medium supplemented
with 10% fetal calf serum and incubated for 48 h at 37 °C and 5% CO2
in a humidiﬁed chamber. Medium conditioned by the cells was collect-
ed at the end of the incubation period and centrifuged at 1000 rpm to
remove all the cells. The clariﬁed medium was then aliquoted and
stored at 4 °C or−20 °C until further use.
Osteoblast and adipocyte differentiation of primary mouse osteoblastic
progenitors
To prepare primary murine osteoblastic progenitors, calvaria were
excised from newborn C57BL/6 mice, washed in RPMI 1640 medium,
and digested in α-MEM medium containing 0.1% collagenase type A
and 0.05% trypsin–EDTAat 37 °C for 20 min, 30 min and 90 min respec-
tively [1]. The supernatant from the ﬁrst two digestions was discarded,
and the cell pellet from the third digestion was resuspended in serum
free α-MEM medium, washed and plated onto 100 mm dishes and
grown in α-MEM medium supplemented with 10% FCS, 1% glutamine,
1% streptomycin and 1% penicillin until conﬂuent.
Upon reaching conﬂuence, the expanded cells were placed in osteo-
genic medium (α-MEMmedium supplemented with 10% FBS, 1% strep-
tomycin and 1% penicillin, 10 mM β-glycerophosphate and 50 μg/ml
ascorbic acid) in the absence or presence of rHPSE (50 ng/ml) or in a
1:1 mixture of osteogenic medium and conditioned medium (CM) from
CAG myeloma HPSE-low or HPSE-high cells. In a separate experiment,
the primary murine osteoblastic progenitors were cultured in the above
conditions with or without DKK1 inhibitor (3.0 mM). The medium was
replaced every 3 days and cell proteinwas isolated at the times indicated.
The same populations of primary murine osteoblastic progenitors
were also cultured in adipocyte differentiation medium (α-MEMFig. 2.Myeloma tumor cell expression of heparanase negatively correlates with the level of ost
representativemyeloma patient bonemarrow biopsy specimens. Patient 2 (Pat#2): HPSE stain
HPSE staining is low (brown stained cells); osteocalcin staining is high (arrows). Note: balloon
examined. Original magniﬁcation, ×400.medium supplemented with 10% FBS, 1% streptomycin and 1% penicil-
lin, 10 μg/ml insulin, 0.25 μM dexamethasone and 0.5 mM 1-methyl-
3-isobutylxanthine) in the absence or presence of rHPSE or with the
1:1 addition of the CM of CAGHPSE-low orHPSE-high cells. Cultureme-
dium was changed every 3 days and protein and conditioned medium
were collected at day 10.
ALP, Von Kossa and Oil Red O staining
After primary murine calvarial osteoblastic progenitors were cul-
tured in osteogenic medium for 14 days, alkaline phosphatase (ALP)
staining for the evaluation of recruitment into the osteoblastic lineage
was performed using an ALP kit according to the manufacturer's in-
structions (Sigma). Von Kossa staining was performed at day 21 of cell
culture for themeasurement of matrix mineralization and as a measure
of the differentiation of mature osteoblasts. Similarly, Oil Red O staining
was performed on the cells cultured toward adipocytes for 10 days. All
staining was performed following the manufacturer's recommenda-
tions as we have described [20].
Western blotting
Equal amounts of protein (80 μg) were subjected to 4–12%
gradient SDS-PAGE (BioRad) and transferred to nitrocellulose mem-
brane (Schleicher and Schuell, Dassel, Germany) [33]. Transferred
proteins were probed with appropriate antibodies and visualized
using an enhanced chemiluminescence system (AmershamBiosciences,
Buckinghamshire, UK). Western blots were quantiﬁed by NIH ImageJ
software version 1.45.
Enzyme-linked immunosorbent assay (ELISA)
Human DKK1 levels in the conditioned medium from HPSE-low and
HPSE-high CAG cells were measured using hDKK1 Quantikine ELISA kit
(R&D Systems). Mouse DKK1 levels in conditionedmedium from prima-
ry murine osteoblastic progenitor cells, C3H10T1/2 pre-osteoblastic cells
and ST2 stromal cells cultured in the absence or presence of rHPSE wereeocalcin in the bone marrow of myeloma patients. Heparanase and osteocalcin staining of
ing is high (brown stained cells); osteocalcin staining is low (arrows). Patient 28 (Pat#28):
shaped, unstained cells are adipocytes. Images are representative of the 28 biopsy samples
13J. Ruan et al. / Bone 57 (2013) 10–17measured by mDKK1 Quantikine ELISA (R&D Systems). All assays were
performed according to the protocols provided by the manufacturers.
Statistical analysis
Statistical comparisons between two experimental groups were
analyzed by Student's t test. ANOVAwas employed for statistical analy-
ses amongmultiple groups, followed by a post-hoc Bonferroni test. The
correlations between heparanase and osteocalcin expression inMMpa-
tients' samples were assessed using Spearman correlation coefﬁcient.
P b 0.05 was considered statistically signiﬁcant and is reported as such.Fig. 3. CM from heparanase-high myeloma cells shifts osteoblast progenitor cells from different
cells harvested from the calvaria of new-born C57BL6micewere cultured in the CMofHPSE-low
3 days. ALP (day 14), Von Kossa (day 21) and Oil Red O (day 14) staining performed. ALP stai
were quantiﬁed using ImageJ software. Osteoblast number in HPSE-low CM vs. HPSE-high CM
in HPSE-low CM vs. HPSE-high CM group: 847 ± 59 nodules/mm2 vs. 58 ± 26 nodules/mm2
114 cells/mm2 vs. 2869 ± 143 cells/mm2 (P = 0.006). (B) Protein was isolated from cultured
14 cells. Left: Western blot; right: quantiﬁcation of Runx2 and PPARγ. Each bar represents the a
parison in each panel. (C) Primary osteoblast progenitor cells were cultured in the CM of HPSE
plate). Left: Oil Red O staining was performed on day 10 of culture. Right: The number o
average ± SEM from quadruplicate wells of two independent experiments.Results
Heparanase suppresses bone formation locally and systemically in the
animal model of myeloma
To determine the effects of heparanase expression by myeloma
cells on mesenchymal lineage cells, we ﬁrst examined the effect of
heparanase on osteoblastogenesis and parameters of bone formation
by evaluating osteoblast parameters in SCID-hu mice [36].
Wemeasured osteocalcin expression, a marker of mature osteoblast
differentiation, in histologic sections of engrafted bone [23]. Theiating into osteoblasts to differentiating into adipocytes. (A) Primary osteoblast progenitor
or HPSE-high cells with equal volume of osteogenicmedium,withmedium changed every
ned osteoblasts, Von Kossa stained mineralized nodules and Oil Red O stained adipocytes
group: 138 ± 44 cells/cm2 vs. 50 ± 17 cells/cm2 (P b 0.01); mineralized nodule number
(P b 0.0001); and adipocyte number in HPSE-low CM vs. HPSE-high CM group: 1152 ±
cells at day 14. Western blots were performed for Runx2 and PPARγ expression in day
verage ± SEM from two independent experiments. Signiﬁcance is indicated for each com-
-low or HPSE-high cells with equal volume of adipocyte differentiation medium (12-well
f Oil Red O stained adipocytes in each well was enumerated. Each bar represents the
Fig. 4. CM from HPSE-high cells inhibits Wnt signaling in osteoblast progenitor cells via
DKK1. (A) CAG cells from three different heparanase transfections using different vectors
(pcDNA3 or pIRES2 or pIRES2-pluc) were cultured in serum free medium for two days.
Theconditionedmediumwas collected, and the levels of humanDKK1 in the CMweremea-
sured by ELISA (HPSE-low [L], HPSE-high [H]). Each bar represents the average ± SD from
two independent experiments. Signiﬁcance is indicated for each comparison. (B) Primary
osteoblast progenitor cells were cultured in an equal volume of CM of HPSE-low or HPSE-
high cells or osteogenic medium with or without DKK1 inhibitor (3.0 mM) for 10 days
(medium changed every 3 days). Cells were harvested for Western blot and stained with
antibodies against active-β-catenin; total-β-catenin and β-actin.
14 J. Ruan et al. / Bone 57 (2013) 10–17analysis revealed that the number of osteocalcin-positive osteoblasts
was signiﬁcantly diminished in both primary (injected with tumor
cells) and contralateral (not injected with tumor cells) engrafted
bones of the mice bearing HPSE-high tumor, compared to animals
bearing tumors formed by HPSE-low cells (Figs. 1A–B). These data pro-
vided the ﬁrst direct experimental evidence that osteoblastogenesis
was inhibited by heparanase in vivo. Interestingly, immunohistochemi-
cal staining for human kappa light chain, a speciﬁc marker of CAG
myeloma cells, revealed no detectable tumor cells in uninjected contra-
lateral grafts (data not shown), suggesting that the inhibition of
osteoblastogenesis was humoral and not due tomyeloma tumormetas-
tasis to the contralateral graft.
The level of osteocalcin expression negatively correlates with the level of
heparanase expression in the bone marrow of myeloma patients
We next investigated the correlation between heparanase expres-
sion and osteocalcin expression in myeloma patients, using primary
bone marrow core biopsy specimens obtained from myeloma patients.
Speciﬁc immunohistochemical staining for heparanase and osteocalcin
was performed on 28 myeloma patient bone marrow core biopsy spec-
imens. We identiﬁed a signiﬁcant negative correlation (r = −0.62,
P b 0.001) between heparanase expression by myeloma cells and
osteocalcin expression by bone marrow cells (Fig. 2 and Supplementary
Table 1). This ﬁnding, in conjunction with earlier data that heparanase
expression is positively correlated with RANKL expression [36], suggests
that heparanase is an important driver of both the pro-osteoclastic and
anti-osteoblastic phenotype characteristics ofmyeloma bone disease. In-
terestingly, we also observed a higher population of adipocytes in the
bonemarrowofmyelomapatientswith the high levels of heparanase ex-
pression (Fig. 2).
Conditioned medium (CM) of HPSE-high cells inhibits osteoblastic
differentiation and mineralization and promotes adipocyte differentiation
of osteoblast progenitor cells
Primary calvarial osteoblast progenitor cells were cultured 1:1 in the
CM from HPSE-low or HPSE-high cells and osteogenic medium as indi-
cated (Fig. 3A). Osteoblast differentiation (ALP staining) and minerali-
zation (Von Kossa staining) were signiﬁcantly suppressed by the CM
of HPSE-high cells, compared to CM of HPSE-low cells. Conversely, sig-
niﬁcantly higher numbers of adipocytes were observed in cells cultured
with HPSE-high CM versus HPSE-low CM (Fig. 3A), suggesting that the
CM of HPSE-high cells supports the differentiation ofmesenchymal pro-
genitors toward the adipocyte lineage.
To begin to understand the mechanism(s) involved in the sup-
pression of osteoblastogenesis, we next performed Western blot
analysis. A signiﬁcant decrease in Runx2 expression (a marker of
osteoblastogenesis) and increase in PPAR-γ expression (a marker of
adipogenesis) were observed in HPSE-high CM treated cells, compared
toHPSE-lowCM treated cells (Fig. 3B). In a separate experiment, prima-
ry murine osteoblast progenitor cells were cultured in the CM of HPSE-
low or HPSE-high cells with 1:1 adipocyte differentiation medium for
10 days. Oil Red O staining demonstrated a signiﬁcant increase in adi-
pocytes in the presence of HPSE-high CM, compared with HPSE-low
CM (Fig. 3C). Taken together, these data suggest that HPSE-highmyelo-
ma cells secrete soluble factor(s) to inhibit osteoblastogenesis and
promote adipogenesis, even if the cells are in a pro-osteoblastogenic en-
vironment in vitro.
Heparanase enhances DKK1 expression and secretion by myeloma cells,
resulting in inhibition of Wnt signaling pathway in osteoblast progenitors
To identify what soluble factor(s) secreted by HPSE-high myeloma
cells may be responsible for the decreased osteoblastogenesis and in-
creased adipogenesis, we measured the levels of known regulatorstransforming growth factor beta (TGF-β), Bone Morphogenetic Protein
2 (BMP-2) and Dickkopf1 (DDK1) in the CM of HPSE-low and HPSE-
high cells by ELISA. There was no signiﬁcant difference in the levels of
TGF-β and BMP-2 in the CM of the two types of cell lines (data not
shown). However, a signiﬁcant increase in DKK1 was found in the CM
of three differentHPSE-high expressing cell lines, compared to the com-
parable HPSE-low cells (Fig. 4A).
In addition, decreased β-catenin activation was observed in primary
osteoblast progenitor cells cultured in the CM of HPSE-high cells
(Fig. 4B), which was rescued by the addition of a potent and selective
DKK1 inhibitor (Fig. 4B). These data demonstrate that the canonical
Wnt signaling pathway was inhibited by increased DKK1 secretion
from HPSE-high myeloma cells.Heparanase directly stimulates DKK1 secretion by osteoblast progenitor
and shifts these cells from osteoblastogenesis to adipogenesis by inhibiting
Wnt signaling
We identiﬁed a high level of human heparanase uptake by murine
C3H10T1/2 osteoblast precursor cells cultured in CM of human HPSE-
high cells or in the presence of exogenous human rHPSE (Fig. 5A).
Since osteoblast progenitors have been shown to produce DKK1 [24],
we determined whether heparanase uptake by osteoblast progenitors
can stimulate DKK1 secretion. Equal numbers of primary mouse osteo-
blast progenitor cells, C3H10T1/2 and ST2 pre-osteoblast/stromal cells
were cultured in osteoblast growth medium with or without rHPSE
(100 ng/ml) for 3 days. ELISA analysis revealed a signiﬁcant increase
in the levels of DKK1 in the CM of the cells treated with rHPSE
(Fig. 5B). Moreover, primary osteoblast progenitor cells cultured in the
presence of rHPSE resulted in a dramatic reduction of the levels of the
active β-catenin (Fig. 5C), and this inhibition was blocked by DKK1 in-
hibitor (Fig. 5C). In addition, ALP and Oil Red O Staining demonstrated
Fig. 5. rHPSE stimulatesDKK1 secretion fromosteoblast progenitor and stromal cells, inhibits osteoblastogenesis, andpromotes adipogenesis by inhibitingWnt signaling pathway in these cells.
(A) Human heparanase is detectable in cell lysates of C3H10T1/2 cells after the cells were cultured in CM of HPSE-low and HPSE-high CAG cells (upper panel) or in the presence of human
rHPSE (100 ng/ml) (lower panel) for 3 days. (B) Primarymurine osteoblast progenitor cells, C3H10T1/2 pre-osteoblastic cells, and ST2 stromal cells were cultured in the absence or presence
of rHPSE (100 ng/ml) for 3 days, and the level of murine DKK1 in the CMmeasured by ELISA. Each bar represents the Mean ± SD of 2 measurements. Signiﬁcance is indicated in the panel.
(C) Primary osteoblast progenitor cells cultured in osteogenic medium in the absence or presence of rHPSE (100 ng/ml) with or without DKK1 inhibitor (3.0 mM) for 10 days (medium
changed every 3 days). Cellswere harvested forWestern blot and stainedwith antibodies against active-β-catenin, total-β-catenin andβ-actin (left). The activeβ-catenin bands fromWestern
blot were quantiﬁed by ImageJ from two independent experiments (right). (D) ALP andOil Red O stainingwere performed at day 10 for evaluation of osteoblast and adipocyte differentiation.
ALP positive osteoblast cells and Oil Red O stained adipocyte colonies were enumerated from two independent experiments (Mean ± SEM). Signiﬁcance is indicated in each panel.
15J. Ruan et al. / Bone 57 (2013) 10–17a corresponding and signiﬁcant inhibition of osteoblast differentiation
and signiﬁcant stimulation of adipocyte differentiation (Fig. 5D).
Discussion
Bone is a dynamic tissue that is constantly being remodeled [30]. In
normal bone remodeling, osteoclasts resorb old and damaged bonebefore osteoblasts follow and synthesize and mineralize new bone in
an exquisitely balanced or coupled process [31]. The balance between
osteoclast-mediated bone resorption and osteoblast-mediated bone
formation is the key for maintaining healthy bone metabolism. Myelo-
ma bone disease is the result of an increase in bone resorption and a de-
crease in bone formation [14,17,27], driving a major imbalance in the
two processes.
16 J. Ruan et al. / Bone 57 (2013) 10–17Wehave shown previously that heparanase enhances the expression
and secretion of RANKL by myeloma cells [26,36], thereby directly stim-
ulating osteoclastogenesis and bone resorption. In the present study, we
investigated whether osteoblast differentiation and activity were regu-
lated by myeloma cells expressing heparanase. Strikingly, heparanase
expression by myeloma cells that stimulates osteoclastogenesis [26,36]
also decreased osteoblastogenesis (and likely bone formation) by
inhibiting osteoblasts and stromal cells in the bone microenvironment.
The immunostaining of osteocalcin in engrafted bones harvested
from SCID-hu mice and in primary bone marrow core biopsies from
myeloma patients demonstrated a signiﬁcant negative correlation be-
tween heparanase expression by myeloma cells and the numbers of
osteocalcin-positive osteoblast cells in bone. Importantly, the inhibition
of osteocalcin-staining and bone formation observed in the engrafted
bones occurs not only in primary tumor-injected bones, but also in con-
tralateral bones where tumor cells were not injected or detected. This
strongly suggests that heparanase-expressing myeloma cells decrease
the numbers of osteocalcin-positive cells and induce the inhibition of
osteoblastogenesis in distal bones prior to the arrival of tumor cells by
secreting soluble inhibitor(s) of osteoblastogenesis. This hypothesis
was conﬁrmed by culturing primary osteoblast progenitor cells with
the conditioned medium of HPSE-high or HPSE-low myeloma cells.
The results demonstrated that the conditioned medium of HPSE-high
cells was capable of inhibiting both osteoblast progenitor differentiation
andmineralization. Perhapsmost surprisingly, we found that the condi-
tioned medium of HPSE-high cells also drives these same progenitor
cells toward adipocytes. Further studies demonstrated that the shift in
cell fate was induced by increased Dickkopf1 (DKK1) secretion by
HPSE-high cells.
DKK1 is a well-characterized inhibitor of canonical Wnt/β-catenin
signaling [24]. Wnt/β-catenin is a critical signaling pathway considered
essential for osteoblastogenesis [6,8]. DKK1 selectively binds to theWnt
receptors Lrp5 or Lrp6, thereby blocking the ability ofWnt ligands to in-
teract with these receptors, speciﬁcally blocking the canonical Wnt sig-
naling pathway and thus inhibiting osteoblast differentiation and bone
formation [22]. In contrast to the function of Wnt signaling to enhance
osteoblast differentiation, Wnt/β-catenin signaling inhibits adipocyte
differentiation [7,12,13]. In the present study, a signiﬁcant increase of
DKK1 secretion in HPSE-highmyeloma cells was observed. Subsequent-
ly, a signiﬁcant inhibition of stable (active) β-catenin expression [8] in
osteoblast progenitors treated with conditioned medium from HPSE-
high cellswas observed. Importantly, the inhibition ofβ-catenin expres-
sion was completely rescued by the addition of a speciﬁc DKK1 inhibi-
tor, conﬁrming that HPSE-high myeloma cells induce the inhibition of
osteoblastogenesis and the promotion of adipogenesis via suppression
of the canonical Wnt signaling pathway by DKK1.
In addition to myeloma cells, it has been demonstrated that pre-
osteoblasts and pre-adipocytes also secrete DKK1 [24]. Our data demon-
strate that the heparanase secreted by HPSE-high myeloma cells can be
taken-up by osteoblast progenitors and bone marrow cells, and in turn,
stimulate DKK1 secretion by these normal cells. The osteoblast progen-
itor secretedDKK1 inhibitsWnt signaling in osteoblast progenitors in an
autocrine/paracrine fashion, thereby contributing to the inhibition of
osteoblastogenesis and the promotion of adipogenesis. Indeed, ALP
and Oil Red O staining revealed a remarkable decrease in the number
of osteoblasts and an increased number of adipocytes in progenitor
cells cultured with either conditioned medium of HPSE-high cells or
rHPSE. If recapitulated in vivo, this process, regulated by heparanase,
could directly and/or indirectly contribute to the imbalance between
bone resorption and bone formation characteristic of myeloma bone
disease. In addition, recent evidence suggests that bone marrow adipo-
cytes are an endocrine organ, secreting growth factors and cytokines
that regulate many physiological and pathological events [4,28]. The
role of adipocytes in multiple myeloma progression, besides its contri-
bution to bone destruction, is currently the focus of intense scrutiny in
our laboratory.Conclusion
The results presented here demonstrate that heparanase expression
by myeloma cells can alter the fate of osteoblast progenitor cells,
directing cellular differentiation toward adipocytes rather than osteo-
blasts. The switch in differentiation involved enhanced PPAR-γ expres-
sion, decreased Runx2 and high levels of DKK1 secretion from both
myeloma cells and bone marrow cells, resulting in the inhibition of
Wnt/β-catenin signaling in osteoblast progenitors. Collectively, these
data, together with our previous report on the role of heparanase in
stimulating bone resorption [36], demonstrate that myeloma bone dis-
ease is the result of a combination of enhanced bone resorption and re-
duced bone formation, both driven by heparanase. Thus, these data also
provide the rationale to target heparanase with heparanase inhibitors
for the treatment of myeloma bone disease, whichmay go beyond con-
ventional approaches that target bone resorption. Further studies will
determine the extent to which enhanced adipogenesis contributes to
myeloma bone disease and tumor progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2013.07.024.
Conﬂict of interest
The authors disclose no potential conﬂicts of interest.
Acknowledgments
This work was supported by grants from the National Cancer Insti-
tute (CA151538 [YY], CA138340 and CA135075 [RDS]), the Multiple
Myeloma Research Foundation (Senior Research Award [YY]), the Carl
L. Nelson Chair of Orthopaedic Creativity (LJS) and the UAMS Transla-
tional Research Institute (TRI) (CTSA grant award #1 UL1TR000039).
The authors also thank Dr. Israel Vlodavsky (Technion, Haifa, Israel)
for providing the rHPSE andheparanase antibodies, Dr. ShiWei for help-
ing with osteocalcin staining on the bone marrow specimens of myelo-
ma patients, Dr. Majd Zayzafoon and Dr. Yi-ping Li for providing the
primary murine osteoblastic progenitors, and Dr. Kun Yuan for the sta-
tistical analyses.
References
[1] Bakker AD, Klein-Nulend J. Osteoblast isolation frommurine calvaria and long bones.
Methods Mol Biol 2012;816:19–29.
[2] Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteogly-
cans in health and disease: new concepts for heparanase function in tumor progres-
sion and metastasis. FEBS J 2010;277:3890–903.
[3] Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to
the uropods of polarized myeloma cells where it promotes adhesion and sequesters
heparin-binding proteins. Blood 2000;96:2528–36.
[4] Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, et al. Neigh-
boring adipocytes participate in the bone marrow microenvironment of multiple
myeloma cells. Leukemia 2007;21:1580–4.
[5] Chen G, Dang YW, Luo DZ, Feng ZB, Tang XL. Expression of heparanase in hepatocel-
lular carcinoma has prognostic signiﬁcance: a tissue microarray study. Oncol Res
2008;17:183–9.
[6] Chen Y, Alman BA. Wnt pathway, an essential role in bone regeneration. J Cell
Biochem 2009;106:353–62.
[7] Christodoulides C, LaudesM, CawthornWP, Schinner S, Soos M, O'Rahilly S, et al. The
Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early
human adipogenesis. J Cell Sci 2006;119:2613–20.
[8] Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012;149:
1192–205.
[9] Cohen E, Doweck I, Naroditsky I, Ben-Izhak O, Kremer R, Best LA, et al. Heparanase is
overexpressed in lung cancer and correlates inversely with patient survival. Cancer
2008;113:1004–11.
[10] Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, et al. Heparanase promotes
growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006;118:
1609–17.
[11] Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation
and formation in multiple myeloma: focus on the receptor activator of NF-kappaB
ligand (RANKL). Exp Hematol 2004;32:685–91.
[12] Gustafson B, Eliasson B, Smith U. Thiazolidinediones increase the wingless-type
MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link
with osteogenesis. Diabetologia 2010;53:536–40.
17J. Ruan et al. / Bone 57 (2013) 10–17[13] Gustafson B, Smith U. The WNT inhibitor Dickkopf 1 and bone morphogenetic pro-
tein 4 rescue adipogenesis in hypertrophic obesity in humans. Diabetes 2012;61:
1217–24.
[14] Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O. Novel aspects of osteo-
clast activation and osteoblast inhibition inmyeloma bone disease. Biochem Biophys
Res Commun 2005;338:687–93.
[15] Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Drebber U, Baldus SE, et al. High
expression of heparanase is signiﬁcantly associated with dedifferentiation and
lymph nodemetastasis in patients with pancreatic ductal adenocarcinomas and cor-
related to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg 2008;12:
1674–81 [discussion 1681–1672].
[16] Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, et al. Identiﬁcation of
active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry
2000;39:15659–67.
[17] Jagannath S. Pathophysiological underpinnings of multiple myeloma progression.
J Manag Care Pharm 2008;14:7–11.
[18] Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, et al. High heparanase activ-
ity in multiple myeloma is associated with elevated microvessel density. Cancer Res
2003;63:8749–56.
[19] Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, et al. Function of
heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res
2008;14:668–76.
[20] Liu L, Aronson J, Huang S, Lu Y, Czernik P, Rahman S, et al. Rosiglitazone inhibits bone
regeneration and causes signiﬁcant accumulation of fat at sites of new bone forma-
tion. Calcif Tissue Int 2012;91:139–48.
[21] Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, et al.
Heparanase inﬂuences expression and shedding of syndecan-1, and its expression
by the bone marrow environment is a bad prognostic factor in multiple myeloma.
Blood 2007;109:4914–23.
[22] Marcellini S, Henriquez JP, Bertin A. Control of osteogenesis by the canonical Wnt
and BMP pathways in vivo: cooperation and antagonism between the canonical
Wnt and BMP pathways as cells differentiate from osteochondroprogenitors to oste-
oblasts and osteocytes. Bioessays 2012;34:953–62.
[23] Mundy GR. Regulation of bone formation by bonemorphogenetic proteins and other
growth factors. Clin Orthop Relat Res 1996:24–8.[24] Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, et al. The role of
Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009;113:517–25.
[25] Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of prote-
ase expression implicates it as a master regulator of the aggressive tumor phenotype
in myeloma. J Biol Chem 2008;283:32628–36.
[26] Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC,
Sanderson RD. Heparanase enhanced shedding of syndecan-1 bymyeloma cells pro-
motes endothelial invasion and angiogenesis. Blood 2010;115:2449–57.
[27] Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435–41.
[28] Sadie-Van Gijsen H, Crowther NJ, Hough FS, Ferris WF. The interrelationship be-
tween bone and fat: from cellular see-saw to endocrine reciprocity. Cell Mol Life
Sci 2012;70:2331–49.
[29] Shafat I, Pode D, Peretz T, Ilan N, Vlodavsky I, Nisman B. Clinical signiﬁcance of urine
heparanase in bladder cancer progression. Neoplasia 2008;10:125–30.
[30] Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone me-
tastasis: how the skeleton affects tumor behavior. Bone 2011;48:6–15.
[31] Suva LJ, Washam C, Nicholas RW, Grifﬁn RJ. Bone metastasis: mechanisms and ther-
apeutic opportunities. Nat Rev Endocrinol 2011;7:208–18.
[32] Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and
inhibition by heparin-derivedmimetics of heparan sulfate. Curr PharmDes 2007;13:
2057–73.
[33] Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, et al. Heparanase pro-
motes the spontaneous metastasis of myeloma cells to bone. Blood 2005;105:
1303–9.
[34] Yang Y,MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, et al. The
syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Blood 2007;110:2041–8.
[35] Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy Jr JD, et al. Heparanase
enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor
growth and metastasis. J Biol Chem 2007;282:13326–33.
[36] Yang Y, Ren Y, Ramani VC, Nan L, Suva LJ, Sanderson RD. Heparanase enhances local
and systemic osteolysis inmultiplemyeloma by upregulating the expression and se-
cretion of RANKL. Cancer Res 2010;70:8329–38.
[37] Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, et al. Soluble
syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002;100:610–7.
